leisure time -WSS

leisure time

author：entertainment 2025-09-14 10:06:09 - browse：1511

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Drug for rare kidney disease narrowly misses mark in clinical trial

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

How Vertex's cystic fibrosis drug is changing patients' lives

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

How Vertex's cystic fibrosis drug is changing patients' lives

Intarcia’s device

Investigation reveals sickle cell patients pressured into sterilizations

focus

leisure time

The next ALS data readout — overdue but important

focus

Medical leaders decry Supreme Court decision on affirmative action

Medical student insurance fails on mental health care coverage

Hepatitis C has a cure — but many Americans still lack access to it

Digital health: a case of mistaken identity

Psychedelics group wrestles with new pharma identity

Study finds gene variants tied to breast cancer risk in Black women

FDA approval of Sarepta Duchenne genetic therapy gives me hope

At flashy new research hub, AstraZeneca lays out ambitious growth goals

United colonoscopy coverage change 'may cost lives,' doctors say

Listen: More tumult at BIO & coercive care for sickle cell patients

hotspot

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Senate HELP committee spars over health care workforce policies

Reports of telehealth's death have been greatly exaggerated

Liver decline slowed by off

Investigation reveals sickle cell patients pressured into sterilizations

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Wikipedia

hotspot

explore

hotspot